New discovery could lead to better treatment and prevention of heart disease, diabetes

Researchers at Cornell University have uncovered a key step in how the human body metabolizes sugar, which could lead to better treatment and prevention of heart disease, obesity and Type 2 diabetes.

Martha S. Field, assistant professor of nutritional sciences, has further characterized the human metabolic pathway by identifying two enzymes that convert the sugar erythrose into erythritol.

This reaction represents the final step in the conversion of glucose to erythritol in human metabolism.

"Your normal diet contains fruits, vegetables and beans and you will inevitably ingest sugar alcohols," said Field, who is the senior author on the paper. Knowing how the body makes sugar alcohols opens up an array of new possibilities for treatment and prevention of heart disease and Type 2 diabetes.

Previous research had shown that elevated levels of erythritol in blood plasma are associated with future increased fat storage and weigh gain, so erythritol serves as a biomarker for weigh gain, possible heart disease and diabetes.

That raises the question: Are elevated levels of erythritol in plasma a causal factor in weight gain, and, if so, could this newly discovered metabolism be a path toward intervention in our fight to combat obesity?

Martha S. Field, Assistant Professor in the College of Human Ecology

Source:
Journal reference:

Schlicker, L. et al. (2019) Unexpected roles for ADH1 and SORD in catalyzing the final step of erythritol biosynthesis. Journal of Biological Chemistry. doi.org/10.1074/jbc.RA119.009049

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-READI consortium launches groundbreaking diabetes data study